Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Jan 11

PMID 35011583

Authors

Gianna M Branella

Harold Trent Spencer

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has been widely successful in the treatment of B-cell malignancies, including B-cell lymphoma, mantle cell lymphoma, and multiple myeloma; and three generations of CAR designs have led to effective FDA approved therapeutics. Traditionally, CAR antigen specificity is derived from a monoclonal antibody where the variable heavy (V) and variable light (V) chains are connected by a peptide linker to form a single-chain variable fragment (scFv). While this provides a level of antigen specificity parallel to that of an antibody and has shown great success in the clinic, this design is not universally successful. For instance, issues of stability, immunogenicity, and antigen escape hinder the translational application of some CARs. As an alternative, natural receptor- or ligand-based designs may prove advantageous in some circumstances compared to scFv-based designs. Herein, the advantages and disadvantages of scFv-based and natural receptor- or ligand-based CAR designs are discussed. In addition, several translational aspects of natural receptor- and ligand-based CAR approaches that are being investigated in preclinical and clinical studies will be examined.

Citing Articles

Targeting BCMA in multiple myeloma: designs, challenges, and future directions.

Hu Y, Xie Y, Wang X, Yang L, Geng H, Yi Z Cancer Immunol Immunother. 2025; 74(3):77.

PMID: 39891674 PMC: 11787132. DOI: 10.1007/s00262-024-03913-0.

Construction and characterization of chimeric FcγR T cells for universal T cell therapy.

Zhao J, Chen M, Li X, Chen Z, Li W, Guo R Exp Hematol Oncol. 2025; 14(1):6.

PMID: 39810257 PMC: 11734343. DOI: 10.1186/s40164-025-00595-x.

Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies.

Li S, Shi L, Zhao L, Guo Q, Li J, Liu Z Nat Commun. 2024; 15(1):9751.

PMID: 39528513 PMC: 11555413. DOI: 10.1038/s41467-024-54150-z.

Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.

Guo J, Zeng X, Zhu Y, Yang D, Zhao X J Transl Med. 2024; 22(1):367.

PMID: 38637885 PMC: 11025286. DOI: 10.1186/s12967-024-05174-y.

Novel CAR-T cells targeting TRKB for the treatment of solid cancer.

Liang D, Tang J, Sun B, He S, Yang D, Ma H Apoptosis. 2024; 29(11-12):2183-2196.

PMID: 38498249 DOI: 10.1007/s10495-024-01936-7.

References

Rogers S, Harrington K, Rhys-Evans P, O-Charoenrat P, Eccles S . Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev. 2005; 24(1):47-69. DOI: 10.1007/s10555-005-5047-1. View

Kubo H, Yagyu S, Nakamura K, Yamashima K, Tomida A, Kikuchi K . Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Mol Ther Oncolytics. 2021; 20:646-658. PMC: 7985479. DOI: 10.1016/j.omto.2021.03.001. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano M . NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Transl Med. 2019; 7(5):105. PMC: 6462666. DOI: 10.21037/atm.2019.01.42. View

Erjala K, Sundvall M, Junttila T, Zhang N, Savisalo M, Mali P . Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006; 12(13):4103-11. DOI: 10.1158/1078-0432.CCR-05-2404. View

Alizadeh D, Wong R, Gholamin S, Maker M, Aftabizadeh M, Yang X . IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. Cancer Discov. 2021; 11(9):2248-2265. PMC: 8561746. DOI: 10.1158/2159-8290.CD-20-1661. View

Aslam M, Abraham J, Mansoor A, Druker B, Tyner J, Keller C . PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2014; 111(17):6383-8. PMC: 4035936. DOI: 10.1073/pnas.1403608111. View

Cerwenka A, Lanier L . Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev. 2001; 181:158-69. DOI: 10.1034/j.1600-065x.2001.1810113.x. View

10.

Chmielewski M, Hombach A, Heuser C, Adams G, Abken H . T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004; 173(12):7647-53. DOI: 10.4049/jimmunol.173.12.7647. View

11.

Wang D, Starr R, Chang W, Aguilar B, Alizadeh D, Wright S . Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020; 12(533). PMC: 7500824. DOI: 10.1126/scitranslmed.aaw2672. View

12.

Hackel B, Ackerman M, Howland S, Wittrup K . Stability and CDR composition biases enrich binder functionality landscapes. J Mol Biol. 2010; 401(1):84-96. PMC: 3927142. DOI: 10.1016/j.jmb.2010.06.004. View

13.

Zhang T, Lemoi B, Sentman C . Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005; 106(5):1544-51. PMC: 1895219. DOI: 10.1182/blood-2004-11-4365. View

14.

Spear P, Barber A, Sentman C . Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology. 2013; 2(4):e23564. PMC: 3654581. DOI: 10.4161/onci.23564. View

15.

Hynes N, MacDonald G . ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21(2):177-84. DOI: 10.1016/j.ceb.2008.12.010. View

16.

Barber A, Zhang T, Megli C, Wu J, Meehan K, Sentman C . Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol. 2008; 36(10):1318-28. PMC: 2638591. DOI: 10.1016/j.exphem.2008.04.010. View

17.

Kahlon K, Brown C, Cooper L, Raubitschek A, Forman S, Jensen M . Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004; 64(24):9160-6. DOI: 10.1158/0008-5472.CAN-04-0454. View

18.

Lipovsek D . Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel. 2010; 24(1-2):3-9. PMC: 3003446. DOI: 10.1093/protein/gzq097. View

19.

Wang W, Singh S, Zeng D, King K, Nema S . Antibody structure, instability, and formulation. J Pharm Sci. 2006; 96(1):1-26. DOI: 10.1002/jps.20727. View

20.

Albitar M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J . Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res. 1999; 23(1):63-9. DOI: 10.1016/s0145-2126(98)00132-5. View